Tracon Pharmaceuticals Reports Positive Results from Trial of TRC105

Tracon Pharmaceuticals has reported positive results from the National Cancer Institute (NCI) phase 1/2 trial of TRC105 and Nexavar (sorafenib) in hepatocellular cancer (HCC). NCI study researchers concluded that the combination of TRC105 and Nexavar was well-tolerated at the recommended single agent doses of both drugs, and that encouraging evidence of activity was observed.

The data “suggest that the combination of TRC105 and Nexavar is active in patients with HCC and support the advancement of this combination into further clinical studies,” said Tracon CEO Charles Theuer. “We expect to report data from the TRACON-sponsored multicenter Phase 1/2 HCC trial in early 2018.”

Leave a Comment